Major Shareholder Fairmount Funds Buys $20M in Recent Public Offering, Increasing Stake to 14.04%

summarizeSummary

Fairmount Funds Management LLC, a 10% owner, invested $20 million in Viridian Therapeutics' recent public offering, increasing its beneficial ownership to 14.04% of outstanding common stock.

check_boxKey Events

• Major Shareholder Increases Stake

  Fairmount Funds Management LLC, a 10% owner, purchased 1,176,470 shares of common stock for $19,999,990.00.

• Participation in Public Offering

  The shares were acquired on May 11, 2026, as part of an underwritten public offering, priced at $17.00 per share.

• New Ownership Percentage

  Fairmount Funds Management LLC now beneficially owns 17,201,800 shares, representing 14.04% of the company's common stock.

• 60-Day Lock-Up Agreement

  The fund entered into a customary 60-day lock-up agreement, restricting sales of shares without underwriter consent.

auto_awesomeAnalysis

Fairmount Funds Management LLC, a significant institutional investor, purchased nearly $20 million worth of Viridian Therapeutics common stock in the company's recent public offering. This substantial investment, representing over 1% of the company's market capitalization, demonstrates strong conviction from a major shareholder, especially following the recent positive clinical data and capital raise. The purchase was made at $17.00 per share, and Fairmount has agreed to a 60-day lock-up period, further signaling a commitment to their investment.